Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/19/2024 | $42.00 → $50.00 | Neutral | UBS | |
| 9/5/2024 | $40.00 → $57.00 | Hold → Buy | Craig Hallum | |
| 8/28/2024 | $30.00 | Overweight | Wells Fargo | |
| 7/10/2024 | $30.00 → $23.00 | Buy → Neutral | Citigroup | |
| 3/4/2024 | $70.00 → $42.00 | Neutral → Sell | UBS | |
| 2/14/2024 | $66.00 → $37.00 | Neutral → Underweight | JP Morgan | |
| 1/4/2024 | $19.50 → $26.00 | In-line → Outperform | Evercore ISI | |
| 12/11/2023 | $95.00 → $72.00 | Buy → Neutral | Citigroup |
8-K - QuidelOrtho Corp (0001906324) (Filer)
424B3 - QuidelOrtho Corp (0001906324) (Filer)
FWP - QuidelOrtho Corp (0001906324) (Subject)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
― Company reinstates 2024 financial guidance ― ― Drives cost-savings and growth initiatives ― ― Strengthens leadership team and aligns organization for improved effectiveness ― Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) Reported revenue was $727 million Recurring revenue1 was $598 million as reported with no significant change in constant currency, excluding COVID-19 and U.S. Donor Screening revenue Labs revenue grew 4% as reported and 5% in constant currency GAAP operating expenses2 of $242 million decreased by $13 million; non-GAAP operating expenses of $232 million decreased by $17 million, reflecting ongoing implementa
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7%Net income of $57.8 million; Adjusted EBITDA of $302.5 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.26Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. "Our team delivered another quarter o
QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its third quarter 2024 ended September 29, 2024, after the market close on Thursday, November 7, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelort
UBS resumed coverage of QuidelOrtho with a rating of Neutral and set a new price target of $50.00 from $42.00 previously
Craig Hallum upgraded QuidelOrtho from Hold to Buy and set a new price target of $57.00 from $40.00 previously
Wells Fargo initiated coverage of Avantor with a rating of Overweight and set a new price target of $30.00
4 - QuidelOrtho Corp (0001906324) (Issuer)
RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform
Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi
QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.
RADNOR, Pa., Nov. 20, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will be participating in a fireside chat at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Tuesday, December 3, at 9:10 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and gl
Agreement Expands Access to Pioneering Proteomics Technology Across the U.S. and Canadian Markets Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE:AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada streamlined access to these innovative proteomics solutions. The distribution agreement enables Avantor to offer Qu
QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company's common stock ("Common Stock"). The Selling Stockholder will receive all of the proceeds from the Offering. The Company is not selling any shares of Common Stock in the Offering and will not receive any proceeds from the Offering. Goldman Sachs & Co. LLC is acting a
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s